SCHEMBL10123979

SCHEMBL10123979

CCN(CC)c1ccc2c(-c3ccccc3C(=O)OC(C)(C)C)c3ccc(=[N+](CC)CC)cc-3oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ BLM P54132 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ PPARG P37231 1/20 0.58
▸ RXFP1 Q9HBX9 1/20 0.58
▸ NCOR2 Q9Y618 1/20 0.58
▸ TGM2 P21980 1/20 0.52
▸ FPR2 P25090 4/20 0.51
▸ CHRM1 P11229 1/20 0.47
▸ AVPR2 P30518 4/20 0.44
▸ TLR7 Q9NYK1 1/20 0.43
▸ ABCB1 P08183 1/20 0.43
▸ CFTR P13569 1/20 0.42
▸ PAX8 Q06710 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ GOPC Q9HD26 1/20 0.42
▸ THRB P10828 1/20 0.41
▸ RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9007850 0.91 USP2 (0.59) USP2MEN1BLMKMT2APOLB
SCHEMBL14393084 0.90 USP2 (0.58) USP2MEN1BLMKMT2APOLB
SCHEMBL10298327 0.90 USP2 (0.58) USP2MEN1BLMKMT2APOLB
SCHEMBL13033323 0.90 USP2 (0.58) USP2MEN1BLMKMT2APOLB
Hydrochloric Acid SCHEMBL23064866 0.89 USP2 (0.57) USP2MEN1BLMKMT2APOLB
SCHEMBL10124264 0.88 USP2 (0.56) USP2MEN1BLMKMT2APOLB
Rhodamine B SCHEMBL10000882 0.88 MEN1 (0.61) USP2MEN1BLMKMT2APOLB
SCHEMBL29593395 0.88 MEN1 (0.61) USP2MEN1BLMKMT2APOLB
SCHEMBL3903552 0.88 MEN1 (0.61) USP2MEN1BLMKMT2APOLB
Hydrochloric Acid SCHEMBL17626403 0.87 TGM2 (0.53) USP2MEN1BLMKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944752-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2018-04-17 — — US disclosed
US-9944754-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2018-04-17 — — US disclosed
US-20170253699-A1 BLOCK COPOLYMERS FOR STABLE MICELLES INTEZYNE TECHNOLOGIES, INC. 2017-09-07 — — US disclosed
US-20170240703-A1 BLOCK COPOLYMERS FOR STABLE MICELLES INTEZYNE TECHNOLOGIES, INC. 2017-08-24 — — US disclosed
US-9499665-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2016-11-22 — — US disclosed
US-20160264732-A1 BLOCK COPOLYMERS FOR STABLE MICELLES INTEZYNE TECHNOLOGIES, INC. 2016-09-15 — — US disclosed
US-20150368401-A1 BLOCK COPOLYMERS FOR STABLE MICELLES INTEZYNE TECHNOLOGIES, INC. 2015-12-24 — — US disclosed
US-20150232616-A1 HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS INTEZYNE TECHNOLOGIES, INC. 2015-08-20 — — US disclosed
US-9078930-B2 Block copolymers for stable micelles INTEZYNE TECHNOLOGIES, INC. (US) 2015-07-14 — — US disclosed
US-8980326-B2 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents INTEZYNE TECHNOLOGIES, INC. (US) 2015-03-17 — — US disclosed
US-7612153-B2 conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-03 — — US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 — — US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 — — US disclosed
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-04-09 — — US disclosed
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 — — US disclosed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 — — US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 — — US disclosed
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof INTEZYNE TECHNOLOGIES (US) 2008-08-07 — — US disclosed
US-20080035243-A1 Covalent modification of metal surfaces INTEZYNE TECHNOLOGIES (US) 2008-02-14 — — US disclosed
US-20080035243-A1 Covalent modification of metal surfaces INTEZYNE TECHNOLOGIES (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080035243-A1 Covalent modification of metal surfaces ITGAL, ITGA1, ITGA5 USP2 1889/4885MEN1 3171/4885BLM 2386/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR USP2 1451/4885MEN1 227/4885BLM 2493/4885
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof LNPEP, GNE, DNPEP USP2 253/4885MEN1 2987/4885BLM 2721/4885
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS LIPA, LPXN, CD47 USP2 1069/4885MEN1 161/4885BLM 469/4885
US-20080274173-A1 Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery CLTB, SLC1A5, CLTA USP2 213/4885MEN1 2136/4885BLM 686/4885
US-20160264732-A1 BLOCK COPOLYMERS FOR STABLE MICELLES ABCB4, CLTB, EPHA2 USP2 735/4885MEN1 1385/4885BLM 111/4885
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups GNE, EPRS1, ALG1 USP2 746/4885MEN1 2092/4885BLM 1345/4885
US-20170240703-A1 BLOCK COPOLYMERS FOR STABLE MICELLES ABCB4, CLTB, EPHA2 USP2 735/4885MEN1 1385/4885BLM 111/4885
US-20170253699-A1 BLOCK COPOLYMERS FOR STABLE MICELLES ABCB4, CLTB, EPHA2 USP2 735/4885MEN1 1385/4885BLM 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback